| UniProt ID | CASPA_HUMAN | |
|---|---|---|
| UniProt AC | Q92851 | |
| Protein Name | Caspase-10 | |
| Gene Name | CASP10 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 521 | |
| Subcellular Localization | ||
| Protein Description | Involved in the activation cascade of caspases responsible for apoptosis execution. Recruited to both Fas- and TNFR-1 receptors in a FADD dependent manner. May participate in the granzyme B apoptotic pathways. Cleaves and activates caspase-3, -4, -6, -7, -8, and -9. Hydrolyzes the small- molecule substrates, Tyr-Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC.; Isoform 7 can enhance NF-kappaB activity but promotes only slight apoptosis.; Isoform C is proteolytically inactive.. | |
| Protein Sequence | MKSQGQHWYSSSDKNCKVSFREKLLIIDSNLGVQDVENLKFLCIGLVPNKKLEKSSSASDVFEHLLAEDLLSEEDPFFLAELLYIIRQKKLLQHLNCTKEEVERLLPTRQRVSLFRNLLYELSEGIDSENLKDMIFLLKDSLPKTEMTSLSFLAFLEKQGKIDEDNLTCLEDLCKTVVPKLLRNIEKYKREKAIQIVTPPVDKEAESYQGEEELVSQTDVKTFLEALPQESWQNKHAGSNGNRATNGAPSLVSRGMQGASANTLNSETSTKRAAVYRMNRNHRGLCVIVNNHSFTSLKDRQGTHKDAEILSHVFQWLGFTVHIHNNVTKVEMEMVLQKQKCNPAHADGDCFVFCILTHGRFGAVYSSDEALIPIREIMSHFTALQCPRLAEKPKLFFIQACQGEEIQPSVSIEADALNPEQAPTSLQDSIPAEADFLLGLATVPGYVSFRHVEEGSWYIQSLCNHLKKLVPRMLKFLEKTMEIRGRKRTVWGAKQISATSLPTAISAQTPRPPMRRWSSVS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 2 | Methylation | ------MKSQGQHWY ------CCCCCCCCC | 52.03 | - | |
| 2 | Acetylation | ------MKSQGQHWY ------CCCCCCCCC | 52.03 | 25953088 | |
| 2 (in isoform 4) | Ubiquitination | - | 52.03 | - | |
| 2 | Ubiquitination | ------MKSQGQHWY ------CCCCCCCCC | 52.03 | - | |
| 3 | Phosphorylation | -----MKSQGQHWYS -----CCCCCCCCCC | 37.94 | 27251275 | |
| 9 | Phosphorylation | KSQGQHWYSSSDKNC CCCCCCCCCCCCCCC | 9.13 | 28796482 | |
| 10 | Phosphorylation | SQGQHWYSSSDKNCK CCCCCCCCCCCCCCE | 20.41 | 28796482 | |
| 11 | Phosphorylation | QGQHWYSSSDKNCKV CCCCCCCCCCCCCEE | 27.19 | 28796482 | |
| 12 | Phosphorylation | GQHWYSSSDKNCKVS CCCCCCCCCCCCEEE | 46.81 | 28796482 | |
| 14 | Ubiquitination | HWYSSSDKNCKVSFR CCCCCCCCCCEEEEC | 67.22 | - | |
| 17 | Ubiquitination | SSSDKNCKVSFREKL CCCCCCCEEEECCCE | 50.75 | - | |
| 23 | Ubiquitination | CKVSFREKLLIIDSN CEEEECCCEEEEECC | 44.32 | - | |
| 90 | Ubiquitination | LYIIRQKKLLQHLNC HHHHHHHHHHHHCCC | 46.20 | - | |
| 99 | Ubiquitination | LQHLNCTKEEVERLL HHHCCCCHHHHHHHC | 54.82 | - | |
| 99 (in isoform 4) | Ubiquitination | - | 54.82 | - | |
| 158 | Ubiquitination | SFLAFLEKQGKIDED HHHHHHHHCCCCCCC | 67.51 | - | |
| 161 (in isoform 4) | Ubiquitination | - | 44.48 | - | |
| 161 | Ubiquitination | AFLEKQGKIDEDNLT HHHHHCCCCCCCCCH | 44.48 | - | |
| 161 | Ubiquitination | AFLEKQGKIDEDNLT HHHHHCCCCCCCCCH | 44.48 | - | |
| 175 | Ubiquitination | TCLEDLCKTVVPKLL HHHHHHHHHHHHHHH | 52.21 | - | |
| 176 | Phosphorylation | CLEDLCKTVVPKLLR HHHHHHHHHHHHHHH | 26.24 | 24719451 | |
| 180 | Ubiquitination | LCKTVVPKLLRNIEK HHHHHHHHHHHHHHH | 48.85 | - | |
| 180 (in isoform 4) | Ubiquitination | - | 48.85 | - | |
| 180 | Ubiquitination | LCKTVVPKLLRNIEK HHHHHHHHHHHHHHH | 48.85 | - | |
| 192 | Ubiquitination | IEKYKREKAIQIVTP HHHHCHHHCEEEECC | 55.62 | - | |
| 192 | Ubiquitination | IEKYKREKAIQIVTP HHHHCHHHCEEEECC | 55.62 | - | |
| 192 (in isoform 4) | Ubiquitination | - | 55.62 | - | |
| 198 | Phosphorylation | EKAIQIVTPPVDKEA HHCEEEECCCCCHHH | 24.41 | 22985185 | |
| 207 | Phosphorylation | PVDKEAESYQGEEEL CCCHHHHHCCCHHHH | 29.78 | 27251275 | |
| 216 | Phosphorylation | QGEEELVSQTDVKTF CCHHHHHCHHHHHHH | 39.73 | 17525332 | |
| 235 | Ubiquitination | PQESWQNKHAGSNGN CHHHHHCCCCCCCCC | 21.52 | - | |
| 250 | Phosphorylation | RATNGAPSLVSRGMQ CCCCCCCCHHHHCCC | 40.65 | 28111955 | |
| 253 | Phosphorylation | NGAPSLVSRGMQGAS CCCCCHHHHCCCCCC | 28.54 | 28111955 | |
| 260 | Phosphorylation | SRGMQGASANTLNSE HHCCCCCCCCCCCCC | 28.95 | 27251275 | |
| 263 | Phosphorylation | MQGASANTLNSETST CCCCCCCCCCCCHHH | 27.34 | 23312004 | |
| 266 | Phosphorylation | ASANTLNSETSTKRA CCCCCCCCCHHHHHH | 45.42 | 23401153 | |
| 268 | Phosphorylation | ANTLNSETSTKRAAV CCCCCCCHHHHHHHH | 41.33 | 28857561 | |
| 269 | Phosphorylation | NTLNSETSTKRAAVY CCCCCCHHHHHHHHH | 28.07 | 28857561 | |
| 270 | Phosphorylation | TLNSETSTKRAAVYR CCCCCHHHHHHHHHH | 31.78 | 28857561 | |
| 271 (in isoform 4) | Ubiquitination | - | 39.55 | - | |
| 271 | Ubiquitination | LNSETSTKRAAVYRM CCCCHHHHHHHHHHC | 39.55 | - | |
| 276 | Phosphorylation | STKRAAVYRMNRNHR HHHHHHHHHCCCCCC | 10.22 | 24719451 | |
| 293 | Phosphorylation | CVIVNNHSFTSLKDR EEEECCCCCCCCCCC | 32.13 | 27251275 | |
| 338 | Ubiquitination | EMEMVLQKQKCNPAH EHHHHHHHCCCCHHH | 47.79 | - | |
| 411 (in isoform 6) | Phosphorylation | - | 21.03 | 22210691 | |
| 435 (in isoform 2) | Phosphorylation | - | 26.65 | 22210691 | |
| 454 (in isoform 6) | Phosphorylation | - | 58.39 | 23285258 | |
| 455 (in isoform 2) | Ubiquitination | - | 15.24 | - | |
| 466 (in isoform 2) | Ubiquitination | - | 3.05 | - | |
| 467 (in isoform 2) | Ubiquitination | - | 36.19 | - | |
| 478 (in isoform 2) | Phosphorylation | - | 50.00 | 23285258 | |
| 478 (in isoform 4) | Phosphorylation | - | 50.00 | 22210691 | |
| 489 | Phosphorylation | EIRGRKRTVWGAKQI HHCCCCCCCCCCEEE | 24.52 | 22210691 | |
| 498 (in isoform 4) | Ubiquitination | - | 11.66 | - | |
| 499 | Phosphorylation | GAKQISATSLPTAIS CCEEEECCCCCCCHH | 24.81 | 23612710 | |
| 500 | Phosphorylation | AKQISATSLPTAISA CEEEECCCCCCCHHC | 31.87 | 28851738 | |
| 503 | Phosphorylation | ISATSLPTAISAQTP EECCCCCCCHHCCCC | 41.75 | 28851738 | |
| 506 | Phosphorylation | TSLPTAISAQTPRPP CCCCCCHHCCCCCCC | 16.32 | 23612710 | |
| 509 (in isoform 4) | Ubiquitination | - | 22.45 | - | |
| 509 | Phosphorylation | PTAISAQTPRPPMRR CCCHHCCCCCCCCCC | 22.45 | 28851738 | |
| 510 (in isoform 4) | Ubiquitination | - | 34.40 | - | |
| 521 | Phosphorylation | MRRWSSVS------- CCCCCCCC------- | 36.13 | 27251275 | |
| 521 (in isoform 4) | Phosphorylation | - | 36.13 | 23285258 |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CASPA_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CASPA_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| 603909 | Autoimmune lymphoproliferative syndrome 2A (ALPS2A) | |||||
| 605027 | Familial non-Hodgkin lymphoma (NHL) | |||||
| 613659 | Gastric cancer (GASC) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-216, AND MASSSPECTROMETRY. | |